AnalystBook Research · Company Intelligence

Beta Bionics, Inc.

BBNXNasdaq

Built from Beta Bionics, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 6.97 safe zoneOK
  • Earnings-manipulation signal · Beneish M -1.85 no flag raisedOK
  • Earnings quality 81/100 accruals in line with cashOK

Where the revenue comes from

Fiscal 2025, as Beta Bionics, Inc. reports it. History and quarterly detail are in the app.

  • I Let$52.1M
  • Single Use Products$23.8M

Leadership changes

From Beta Bionics, Inc.'s own filings, the day they're filed.

  • Gerard Michel · director · appointment

Latest filings

  • 8-K · Company announcement2026-07-29
  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-05-22
  • 8-K · Company announcement2026-05-21
  • 10-Q · Quarterly report2026-04-21
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Beta Bionics, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Beta Bionics, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.